In perhaps the most Silicon Valley startup yet, a South San Francisco AI company thinks it has figured out how to engineer the therapeutic benefits of psychedelics while leaving behind the mind-bending hallucinations that make some people run screaming from the experience.
Mindstate Design Labs, backed by the tech world's biggest names including the founders of OpenAI, Neuralink, and Coinbase, has successfully created what CEO Dillan DiNardo calls "the least psychedelic psychedelic that's psychoactive." Think of it as psychedelic tofu—all the nutritional benefits, none of the overwhelming flavor.
The End of the Wild West Era
This breakthrough comes at a fascinating inflection point for psychedelic medicine. While tech workers in Silicon Valley have been microdosing LSD for years in pursuit of that perfect coding breakthrough, according to The Conversation, the practice has remained frustratingly unpredictable. One tech executive interviewed by KRON4 described the difference: "It's not a party time, what it is, is more creativity because I am more deeply connected to the work that I do."
The problem? Even microdoses can sometimes hit harder than expected, potentially turning a productive workday into an unplanned journey through consciousness—not exactly what you want during a board meeting. Recent research published in Frontiers in Psychiatry found that among 1,116 psychedelic microdosers surveyed, most reported enhanced creativity and productivity, but dosing remained a persistent challenge due to unregulated street drugs.
AI Meets Ancient Medicine
Mindstate's approach represents a quantum leap beyond the trial-and-error methods that have defined both Silicon Valley microdosing culture and traditional psychedelic research. The company's AI platform, called Osmanthus, analyzed over 70,000 "trip reports" from clinical trials, Reddit posts, and even dark web forums to understand exactly how different psychoactive compounds affect human consciousness, according to WIRED.
This digital archaeology project is part of a broader AI revolution in drug discovery that's transforming the pharmaceutical industry. Drug Target Review reports that AI-designed drugs are achieving 80-90% success rates in Phase I trials, compared to traditional approaches that struggle with 40-65% success rates. The AI pharmaceutical market is projected to grow from $1.94 billion in 2025 to $16.49 billion by 2034, according to Coherent Solutions.
The result of Mindstate's computational deep dive is MSD-001, a pharmaceutical formulation of 5-MeO-MiPT (nicknamed "moxy" in certain circles) that produces heightened emotions, enhanced creativity, and brighter color perception without sending users on a six-hour journey through their subconscious.
Beyond the Trip: The Science of Selective Neuroplasticity
What makes Mindstate's breakthrough particularly compelling is how it leverages cutting-edge neuroscience research. Traditional psychedelics work by flooding multiple brain receptor systems simultaneously—like a neurochemical shotgun blast. Recent research published in Science revealed that psychedelics promote neuroplasticity through activation of intracellular serotonin 2A receptors, which explains why some compounds trigger growth without hallucinations while others don't work at all.
MSD-001 specifically targets these intracellular serotonin 2a receptors—the same pathway that makes psilocybin and LSD so therapeutically promising—without triggering the visual hallucinations or ego dissolution that can make traditional psychedelic therapy feel like emotional boot camp. A comprehensive review in Molecular Medicine found that 15 out of 16 recent studies demonstrated clear psychedelic-induced neuroplasticity, particularly in brain regions critical for emotion regulation and memory.
In Phase I trials involving 47 healthy participants, MSD-001 produced measurable psychoactive effects within 30 minutes, peaked around 90 minutes, and was completely safe with no serious adverse events, according to WIRED. Participants reported enhanced imagination and associative thinking—the kind of creative breakthrough that Silicon Valley microdosers chase—without any of the unpredictability.
The Regulatory Reckoning
Mindstate's timing couldn't be better. The company's "psychedelic lite" approach comes in the wake of a crushing regulatory setback for the broader psychedelic medicine field. Last year, the FDA dealt a devastating blow when it rejected MDMA-assisted therapy for PTSD treatment, despite promising clinical trial results, as reported by Science.
The rejection highlighted thorny regulatory questions about combining drug therapy with psychotherapy—questions that Mindstate plans to sidestep entirely. Learning from MDMA's stumble, the company intends to pursue FDA approval for its compounds as standalone drugs, similar to how Spravato (a form of ketamine) is administered under medical supervision without requiring intensive therapy sessions.
"The FDA rejected MDMA not because psychedelics don't work, but because the regulatory framework wasn't ready for therapy-drug combinations," explains Clinical Trial Vanguard. This regulatory uncertainty has sent psychedelic companies scrambling to redesign their trials—exactly the kind of complexity that Mindstate's approach could avoid.
A Tale of Two Cities: The Psychedelic Paradox
The irony isn't lost on observers that while a South San Francisco lab engineers precision psychedelics, just miles away in the city itself, mushroom churches have been operating in a legal gray area. San Francisco is home to at least half a dozen "psychedelic churches" including the Church of Ambrosia, Rising Phoenix Entheogenic Temple, and the Church of Cosmic Consciousness, according to SFGATE.
These establishments, operating under claimed religious exemptions, have been selling psilocybin mushrooms openly while city officials struggle with how to respond. The Church of Ambrosia recently closed its San Francisco location due to expensive building code compliance issues, but the broader mushroom church phenomenon represents the opposite approach from Mindstate—raw, unprocessed psychedelics for spiritual exploration rather than engineered compounds for specific therapeutic goals.
"We want to make sure people have safe access to the sacraments they need," Dave Hodges, founder of the Church of Ambrosia, told SFGATE. The contrast with Mindstate's laboratory approach couldn't be starker—one group views psychedelics as divine sacraments, the other as neurological tools to be optimized through artificial intelligence.
The Billion-Dollar Question
Whether Mindstate's engineered approach represents the future of mental health treatment or just another Silicon Valley attempt to optimize the human experience remains hotly debated. With prescription sales for drugs like Prozac and Zoloft estimated at $50 billion annually worldwide, and the broader mental health market valued at $100 billion, according to Silicon Valley Business Journal, investors are hungry for breakthrough treatments.
The company has already raised $25.5 million and operates from its headquarters at 611 Gateway Boulevard in South San Francisco, according to CB Insights. But expert opinions remain divided on whether removing the "trip" is the right approach.
Rachel Yehuda, director of the Parsons Research Center for Psychedelic Healing at Mount Sinai Health System, argues that traditional psychedelics derive their therapeutic power from their unpredictability and emotional intensity. "Psychedelics are valuable because of their richness, their unpredictability, and the depth that comes from engaging with unconscious material," Yehuda told WIRED.
However, she acknowledges that not every patient seeking relief from depression and anxiety wants to experience intense psychological revelations. Alan Davis, director of the Center for Psychedelic Drug Research at Ohio State University, sees particular promise for patients currently excluded from psychedelic therapy trials due to conditions like psychotic disorders.
Engineering Consciousness, Silicon Valley Style
Mindstate is now working on combination formulations that add other compounds to its "psychedelic tofu" base to target specific therapeutic goals. The company's first combination aims to reduce anxiety, increase insight, and enhance aesthetic perception—essentially creating designer states of consciousness tailored for specific mental health conditions.
"We created the least psychedelic psychedelic that's psychoactive," DiNardo explained to WIRED. "The thesis was, if we essentially stripped out all of those other biochemical interactions, we'd be left with a drug that was quite tofu-like by psychedelic standards."
In a region that's already brought us algorithmic everything—from food delivery to romantic relationships—perhaps it was inevitable that someone would eventually try to debug the psychedelic experience too. The question isn't whether Silicon Valley can engineer better living through chemistry, but whether that engineering preserves what makes these ancient compounds so uniquely powerful in the first place.
As the Bay Area continues its complex relationship with consciousness-altering substances—from corporate microdosing to spiritual mushroom churches to now AI-designed psychedelics—Mindstate represents yet another distinctly local approach to an age-old human quest: the search for healing, creativity, and transcendence, optimized for the modern world.
